BioSpace News Archive

Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary Immugenyx, LLC (“Immugenyx”) has entered into a collaboration agreement with Orgenesis, Inc.

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has announced new long-term data from the open-label-period of the phase 3 VOYAGE 1 clinical trial demonstrating stably maintained rates of skin clearance with Tremfya(R) treatment at week 52 (1 year) and week 156 (3 years) among adult patients with moderate to severe plaque psoriasis.

What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.

Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary, Hemogenyx-Cell S.A. (“Hemogenyx-Cell”) has entered into a further collaboration agreement with Orgenesis, Inc (“Orgenesis”).

Yesterday, researchers at the Massachusetts Institute of Technology (MIT) published research in the journal Science Advances describing yet another CRISPR improvement.

Revenue for the third quarter of 2018 was $40.8 million, a 30% increase compared to $31.5 million for the third quarter of 2017.

Pharmaceutical Care Management Association President and CEO JC Scott issued the following statement on the Administration’s proposed Medicare Part B pricing model

Janssen Announcement Validates AMPEL’s Ranking of Stelara

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 2018 Carestream Health/RSNA Research Scholar Grant to Christine E. Edmonds, M.D. This grant is made possible by Carestream Health’s support of the RSNA R&E Foundation.

Agilent Technologies Inc. today announced that it has been recognized by Forbes as one of the World’s Best Employers.